drugset / Trial / NCT02950857
A Study of EPEG in Beta Thalassemia Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label study in which 6 patients will receive once-weekly subcutaneous injections of EPEG for 4 weeks. Final visit will occur 60 days after study entry
Timeline
- Start
- 2017-06-28
- Primary completion
- 2017-09-27
- Completion
- 2017-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegylated erythropoietin | Unknown | 0.9 ug/kg | Subcutaneous |
| Subject | pegylated erythropoietin | Unknown | 1.2 ug/kg | Subcutaneous |
| Subject | pegylated erythropoietin | Unknown | 1.5 ug/kg | Subcutaneous |